{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:41:53Z","timestamp":1793922113981,"version":"4.8.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The use of bispecific antibodies (BsAbs) in the treatment of relapsed\/refractory multiple myeloma (MM) is showing early promising overall response rates in heavily pretreated patients. Infectious complications related to the use of BsAbs are not well described. We conducted a pooled analysis that included all single-agent BsAbs used in MM with no prior use of different BsAbs. A total of 1185 patients with MM were treated with a BsAb in the studied period (71.6% of the patients treated with an agent targeting B-cell maturation antigen (BCMA). Pooled median follow-up was short at 6.1\u00a0months (7.5 vs 5.2\u00a0months for BCMA vs non-BCMA BsAbs, respectively). Adverse events of interest included all grade neutropenia in 38.6%, all grade infections in 50% (n\u00a0= 542\/1083), all grade cytokine release syndrome in 59.6% (n\u00a0= 706\/1185), grade III\/IV neutropenia in 34.8% (n\u00a0= 372\/1068), grade III\/IV infections in 24.5% (n\u00a0= 272\/1110), grade III\/IV pneumonia in 10% (n\u00a0= 52.4\/506), and grade III\/IV coronavirus disease 2019 in 11.4% (n\u00a0= 45.4\/395) of the patients. Non-BCMA\u2013targeted BsAbs were associated with lower grade III\/IV neutropenia (25.3% vs 39.2%) and lower grade III\/IV infections (11.9% vs 30%) when compared with BCMA-targeted BsAbs. Hypogammaglobulinemia was reported in 4 studies, with a prevalence of 75.3% (n\u00a0= 256\/340) of the patients, with IV immunoglobulin used in 48% (n\u00a0= 123\/256) of them. Death was reported in 110 patients, of which 28 (25.5%) were reported to be secondary to infections. Certain precautions should be used when using BsAbs to mitigate the risk and\/or identify and treat infections promptly.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009435","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T16:57:20Z","timestamp":1677689840000},"page":"3069-3074","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":140,"title":["Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis"],"prefix":"10.1182","volume":"7","author":[{"given":"Farah","family":"Mazahreh","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Mazahreh","sequence":"additional","affiliation":[{"name":"2School of Medicine, Hashemite University, Zarqa, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[{"name":"3Myeloma Institute, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[{"name":"3Myeloma Institute, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[{"name":"3Myeloma Institute, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"3Myeloma Institute, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6208-1676","authenticated-orcid":false,"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[{"name":"3Myeloma Institute, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"3Myeloma Institute, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[{"name":"3Myeloma Institute, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"issue":"1","key":"2023071017082857500_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"2023071017082857500_bib2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023071017082857500_bib3","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"issue":"6","key":"2023071017082857500_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl_1","key":"2023071017082857500_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"issue":"Suppl_1","key":"2023071017082857500_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2021-144921","article-title":"Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma (RRMM),\u201d","volume":"138","author":"Zonder","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023071017082857500_bib7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl_1","key":"2023071017082857500_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A\u00a0phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2023071017082857500_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"issue":"31","key":"2023071017082857500_bib10","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A\u00a0phase I first-in-human study of ABBV-383, a B-cell maturation antigen\u00a0\u00d7 CD3 bispecific t-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"2023071017082857500_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2021-146868","article-title":"Updated phase 1 results from MonumenTAL-1: first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma,\u201d","volume":"138","author":"Krishnan","year":"2021","journal-title":"Blood"},{"issue":"24","key":"2023071017082857500_bib12","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"2023071017082857500_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"2023071017082857500_bib14","article-title":"A Language and Environment for Statistical Computing","author":"Development Core Team","year":"2019","journal-title":"R Foundation for Statistical Computing"},{"issue":"5","key":"2023071017082857500_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"18","key":"2023071017082857500_bib16","first-page":"4088","article-title":"BCMA in multiple myeloma-a promising key to therapy","volume":"10","author":"Kleber","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"10","key":"2023071017082857500_bib17","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"Suppl_1","key":"2023071017082857500_bib18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2021-150757","article-title":"A\u00a0phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma [abstract]","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"issue":"Suppl_1","key":"2023071017082857500_bib19","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2023071017082857500_bib20","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/13\/3069\/2062902\/blooda_adv-2022-009435-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/13\/3069\/2062902\/blooda_adv-2022-009435-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T13:18:23Z","timestamp":1688995103000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/13\/3069\/494747\/Risk-of-infections-associated-with-the-use-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":20,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,7,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009435","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}